- Frozen (CL106) $ 1,800
Cell type: Fibrosarcoma
Transgenes: Firefly luciferase with neomycin resistance (Neo) for selection with G418 and near-infrared fluorescent protein (iRFP; excitation/emission: 690/713nm) with puromycin resistance (Puro) for selection with puromycin
Media: DMEM, 10% FBS, 1% Pen/Strep, 1.25 mg/mL G418, 1 μg/mL puromycin
Description: HT1080-Fluc-Neo/iRFP-Puro is a polyclonal population derived from the fibrosarcoma cell line HT1080 (ATCC® CCL-121™) transduced with a lentiviral vector LV-Fluc-P2A-Neo (LV011) encoding the firefly luciferase (Fluc) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the neomycin resistance gene (Neo) via a P2A cleavage peptide and LV-iRFP-P2A-Puro (LV032) encoding the near-infrared fluorescent protein (iRFP) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the puromycin resistance gene (Puro) via a P2A cleavage peptide
The lentiviral vectors used are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).
Mycoplasma Testing: HT1080-Fluc-Neo/iRFP-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.
Cell Line Authentication: The parental HT1080 cell line was authenticated are certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 9 STR loci including CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA and sex chromosome marker Amelogenin.
In vitro: This is a high firefly luciferase and iRFP expressing cell line suitable for use as a positive control cell line in bioluminescence and fluorescence assays to verify luciferase or iRFP expression respectively in your lentiviral transduced cells.
In vivo: HT1080 cells form tumors post implantation into immunosuppressed mice. The in vivo growth of these tumors can be monitored using noninvasive bioluminescent imaging or noninvasive optical imaging for iRFP.
Please ensure that your optical imaging system has the correct excitation and emission filters for detection of iRFP (excitation/emission: 690/713nm).
Morphology: Low- and high-density cell morphology (200x)
Flow Cytometry for iRFP: HT1080-Fluc-Neo/iRFP-Puro (red) or control (HT1080-Fluc-Puro) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).
Luciferase Assay: 104, 105, or 106 cells were placed in wells of a 96-well plate and 0.3 mg of d-luciferin was added to the indicated wells. The plate was immediately imaged using a Xenogen IVIS Spectrum.
Bioluminescent images showing growth of a subcutaneous HT1080-Fluc tumor in an athymic mouse
107 HT1080-Fluc-Puro cells (Imanis Life catalog #CL076) were injected subcutaneously into the right flanks of female NCR athymic mice. Mice were imaged at day 0 on the day of cell implantation and subsequently at days 7 and 16 using a Perkin Elmer IVIS® Spectrum system, at 10-15 minutes post intraperitoneal injection of D-luciferin at 150 mg/kg. Tumor size was measured using calipers. Data from a representative mouse (ID#6329) is shown.